首站-论文投稿智能助手
典型文献
Acute perimyocarditis following heterologous vaccination of CoronaVac and BNT162b2 SARS-CoV-2 vaccine in an elderly woman
文献摘要:
Inactivated and mRNA SARS-CoV-2 vaccinesare highly efficacious in preventing severe di-sease and mortality. As the antibody level wa-nes over time,[1] booster vaccination is recommen-ded by the World Health Organization after compl-etion of basic vaccination sequence.[2] Heterologous compared to homologous boosting is found to be more immunogenic, generate higher antibody le-vels and may reduce the risk of breakthrough infec-tions.[3] For example, health authorities in Hong Kong and Singapore recommend mRNA vaccines as bo-oster for inactivated vaccine-primed individuals. mRNA vaccines including BNT162b2 and mRNA-1273 are associated with higher risk of myocarditis predominantly in young males,[4] which is also ob-served in mRNA vaccine-boosted, AZD1222-pri-med individuals.[5] However, myocarditis risk is un-known in individuals who are primed with inactiv-ated and heterologously boosted with mRNA vac-cines, particularly in the elderly population.
文献关键词:
作者姓名:
Shing Ching;Chiu Sun Yue
作者机构:
Division of Cardiology,Department of Medicine and Geriatrics,United Christian Hospital,Hong Kong,China
引用格式:
[1]Shing Ching;Chiu Sun Yue-.Acute perimyocarditis following heterologous vaccination of CoronaVac and BNT162b2 SARS-CoV-2 vaccine in an elderly woman)[J].老年心脏病学杂志(英文版),2022(10):785-787
A类:
perimyocarditis,Inactivated,vaccinesare,sease,compl,etion,vels,oster,AZD1222,inactiv
B类:
Acute,following,vaccination,CoronaVac,BNT162b2,SARS,CoV,elderly,woman,highly,efficacious,preventing,severe,mortality,antibody,level,wa,over,booster,ded,by,World,Health,Organization,after,basic,sequence,Heterologous,compared,homologous,boosting,found,be,more,immunogenic,generate,higher,may,reduce,risk,breakthrough,infec,tions,For,example,health,authorities,Hong,Kong,Singapore,recommend,inactivated,primed,individuals,including,associated,predominantly,young,males,which,also,ob,served,boosted,However,known,who,heterologously,particularly,population
AB值:
0.469694
相似文献
Safety and immunogenicity of COVID-19 vaccination among liver transplant recipients in China
Qiu-Ju Tian;Man Xie;Ji-Tao Wang;Yi Wang;Bei Zhang;Jin-Zhen Cai;Xiao-Long Qi;Wei Rao-Division of Hepatology,Liver Disease Center,The Affiliated Hospital of Qingdao University,Qingdao 266000,China;Department of Organ Transplantation,The Affiliated Hospital of Qingdao University,Qingdao 266000,China;Department of Gastroenterology,The Affiliated Hospital of Qingdao University,Qingdao 266000,China;CHESS-COVID-19 Group,Xingtai People's Hospital,Xingtai 054000,China;Department of Clinical Laboratory,The Affiliated Hospital of Qingdao University,Qingdao 266000,China;Department of Immunology,Qingdao University Medical College,Qingdao 266000,China;CHESS Center,Institute of Portal Hypertension,The First Hospital of Lanzhou University,Lanzhou 730000,China
Knowledge about,attitude and acceptance towards,and predictors of intention to receive the COVID-19 vaccine among cancer patients in Eastern China:A cross-sectional survey
Jing Hong;Xiao-wan Xu;Jing Yang;Jing Zheng;Shu-mei Dai;Ju Zhou;Qing-mei Zhang;Yi Ruan;Chang-quan Ling-School of Traditional Chinese Medicine,Naval Medical University,Shanghai 200433,China;Department of Integrative Oncology,Changhai Hospital,Naval Medical University,Shanghai 200433,China;Department of Oncology,The First Affiliated Hospital,Bengbu Medical College,Bengbu 233010,Anhui Province,China;Department of Nursing,Fuyang Cancer Hospital,Fuyang 236000,Anhui Province,China;Department of Cardiac Rehabilitation,Shanghai First Rehabilitation Hospital,Shanghai 200090,China;Department of Radiation Oncology,Anhui Chest Hospital,Hefei 230022,Anhui Province,China;Department of Anesthesiology,Chaohu Hospital,Anhui Medical University,Hefei 238000,Anhui Province,China
Potential medicinal plants involved in inhibiting 3CLpro activity:A practical alternate approach to combating COVID-19
Fan Yang;Xiao-lan Jiang;Akash Tariq;Sehrish Sadia;Zeeshan Ahmed;Jordi Sardans;Muhammad Aleem;Riaz Ullah;Rainer W.Bussmann-The Medical Center of General Practice,Sichuan Academy of Medical Science and Sichuan Provincial People's Hospital,Chengdu 610041,Sichuan Province,China;Xinjiang Institute of Ecology and Geography,Chinese Academy of Sciences,Urumqi 830041,Xinjiang Uygur Autonomous Region,China;Department of Biological Sciences,University of Veterinary and Animal Sciences,Ravi Campus,Pattoki 55300,Pakistan;Consejo Superior de Investigaciones Científicas,Global Ecology Unit,Centre for Ecological Research and Forestry Applications-Consejo Superior de Investigaciones Cientificas-Universitat Autònoma de Barcelona,Bellaterra,Barcelona 08193,Catalonia,Spain;Centre for Ecological Research and Forestry Applications,Cerdanyola del Vallès 08193,Catalonia,Spain;Department of Pharmacognosy,College of Pharmacy,King Saud University,Riyadh 11451,Saudi Arabia;Department of Ethnobotany,Institute of Botany,Ilia State University,Tbilisi 0105,Georgia
Clinical significance of serum IgM and IgG levels in COVID-19 patients in Hubei Province, China ☆
Bai Zhenjiang;Li Qing;Chen Qinghui;Niu Changming;Wei Yu;Huang Hanpeng;Zhao Wei;Chen Nian;Yao Xin;Zhang Qiang;Mu Chuanyong;Feng Jian;Zhu Chuanlong;Li Zhuo;Ding Ming;Feng Binhui;Jin Chaochao;Lu Xiang;Yang Yi;Wu Shuiyan;Shu Xiaochen;Hu Lifang;Qiu Haibo;Huang YingZi-Pediatric Intensive Care Unit, Children’s Hospital of Soochow University, Suzhou, Jiangsu 215025, China;Department of Critical Care Medicine, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, Jiangsu 210009, China;Department of Infectious Diseases, Children’s Hospital of Soochow University, Suzhou, Jiangsu 215025, China;Department of Critical Care Medicine, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210011, China;Department of Respirology, Jiangsu Province Hospital of TCM, Nanjing, Jiangsu 210046, China;Department of Respirology, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu 212001, China;Department of Critical Care Medicine, Sir Run Hospital Nanjing Medical University, Nanjing, Jiangsu 211112, China;Department of Infectious Diseases, The Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 211103, China;Department of Respiratory and Critical Care Medicine, The Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 211103, China;Department of Respirology, Southeast University Zhongda Hospital, Nanjing, Jiangsu 210009, China;Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, China;Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226019, China;Department of Emergency, Children’s Hospital of Nanjing Medical University, Nanjing, Jiangsu 210008, China;Department of Critical Care Medicine, Huangshi Central Hospital, Huangshi, Hubei 435002, China;Department of Oncology, Huangshi Hospital of TCM (Infectious Disease Hospital, Huangshi, Hubei 435002, China;Department of Geriatric Medicine, Sir Run Hospital Nanjing Medical University, Nanjing, Jiangsu 211112, China;Department of Epidemiology, School of Public Health, Medical College of Soochow University, Suzhou, Jiangsu 215031, China;Jiangsu Key Laboratory of Neuropsychiatric Diseases and Institute of Neuroscience, Soochow University, Suzhou, Jiangsu 215031, China
Early assessment of the safety and immunogenicity of a third dose(booster)of COVID-19 immunization in Chinese adults
Yuntao Zhang;Yunkai Yang;Niu Qiao;Xuewei Wang;Ling Ding;Xiujuan Zhu;Yu Liang;Zibo Han;Feng Liu;Xinxin Zhang;Xiaoming Yang-China National Biotec Group Company Limited,Beijing 100024,China;Shanghai Institute of Hematology,State Key Laboratory of Medical Genomics,National Research Center for Translational Medicine at Shanghai,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;Beijing Institute of Biological Products,China National Biotec Group Company Limited,Beijing 100176,China;National Vaccine and Serum Institute,China National Biotec Group Company Limited,Beijing 101111,China;Department of Infectious Diseases,Research Laboratory of Clinical Virology,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China
Seroprevalence of influenza viruses in Shandong,Northern China during the COVID-19 pandemic
Chuansong Quan;Zhenjie Zhang;Guoyong Ding;Fengwei Sun;Hengxia Zhao;Qinghua Liu;Chuanmin Ma;Jing Wang;Liang Wang;Wenbo Zhao;Jinjie He;Yu Wang;Qian He;Michael J.Carr;Dayan Wang;Qiang Xiao;Weifeng Shi-Key Laboratory of Etiology and Epidemiology of Emerging Infectious Diseases in Universities of Shandong,Shandong First Medical University&Shandong Academy of Medical Sciences,Taian 271000,China;School of Public Health,Shandong First Medical University&Shandong Academy of Medical Sciences,Jinan 250117,China;The Department of Infectious Disease,The Second Affiliated Hospital of Shandong First Medical University,Taian 271000,China;Clinical Laboratory,The Department of Clinical Laboratory,Boshan District Hospital,Zibo 255200,China;Clinical Laboratory,The Department of Clinical Laboratory,The Second Affiliated Hospital of Shandong First Medical University,Taian 271000,China;The Department of Cancer Center,Taian Tumor Prevention and Treatment Hospital,Taian 271000,China;National Virus Reference Laboratory,School of Medicine,University College Dublin,Dublin 4,Ireland;International Collaboration Unit,International Institute for Zoonosis Control,Hokkaido University,Sapporo,Hokkaido,001-0020,Japan;Chinese National Influenza Center,National Institute for Viral Disease Control and Prevention,Collaboration Innovation Center for Diagnosis and Treatment of Infectious Diseases,Chinese Center for Disease Control and Prevention,Key Laboratory for Medical Virology,National Health and Family Planning Commission,Beijing 102206,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。